Dwijit GuhaSarkar1, Qin Su1, Guangping Gao1, Miguel Sena-Esteves1. 1. Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts (D.G., Q.S., G.G., M.S.-E.); Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts (D.G., M.S.-E.); Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts (G.G.).
Abstract
BACKGROUND: Complete surgical removal of all glioblastoma (GBM) cells is impossible due to extensive infiltration into brain parenchyma that ultimately leads to tumor recurrence. The current standard of care affords modest improvements in survival. New therapeutic interventions are needed to prevent recurrence. Local AAV-hIFNβ gene delivery to the brain was previously shown to eradicate noninvasive orthotopic U87 tumors in mice. However, widespread CNS gene delivery may be necessary to treat invasive GBMs. Here we investigated the therapeutic effectiveness of systemically infused AAV9-hIFNβ against an invasive orthotopic GBM8 model. METHODS: Mice bearing human GBM8 brain tumors expressing firefly luciferase (Fluc) were treated systemically with different doses of scAAV9-hIFNβ vector. Therapeutic efficacy was assessed by sequential bioluminescence imaging of tumor Fluc activity and animal survival. Brains were analyzed post mortem for the presence and appearance of tumors. Two transcriptionally restricted AAV vectors were used to assess the therapeutic contribution of peripheral hIFNβ. RESULTS: Systemic infusion of scAAV9-hIFNβ vector induced complete regression of established GBM8 tumors in a dose-dependent manner. The efficacy of this approach was also dependent on the stage of tumor growth at the time of treatment. We also showed that peripherally produced hIFNβ contributed considerably to the therapeutic effect of scAAV9-hIFNβ. A comparative study of systemic and unilateral intracranial delivery of scAAV9-hIFNβ in a bilateral GBM8 tumor model showed the systemic route to be the most effective approach for treating widely dispersed tumors. CONCLUSIONS: Systemic delivery of AAV9-IFNβ is an attractive approach for invasive and multifocal GBM treatment.
BACKGROUND: Complete surgical removal of all glioblastoma (GBM) cells is impossible due to extensive infiltration into brain parenchyma that ultimately leads to tumor recurrence. The current standard of care affords modest improvements in survival. New therapeutic interventions are needed to prevent recurrence. Local AAV-hIFNβ gene delivery to the brain was previously shown to eradicate noninvasive orthotopic U87 tumors in mice. However, widespread CNS gene delivery may be necessary to treat invasive GBMs. Here we investigated the therapeutic effectiveness of systemically infused AAV9-hIFNβ against an invasive orthotopic GBM8 model. METHODS:Mice bearing human GBM8 brain tumors expressing firefly luciferase (Fluc) were treated systemically with different doses of scAAV9-hIFNβ vector. Therapeutic efficacy was assessed by sequential bioluminescence imaging of tumor Fluc activity and animal survival. Brains were analyzed post mortem for the presence and appearance of tumors. Two transcriptionally restricted AAV vectors were used to assess the therapeutic contribution of peripheral hIFNβ. RESULTS: Systemic infusion of scAAV9-hIFNβ vector induced complete regression of established GBM8 tumors in a dose-dependent manner. The efficacy of this approach was also dependent on the stage of tumor growth at the time of treatment. We also showed that peripherally produced hIFNβ contributed considerably to the therapeutic effect of scAAV9-hIFNβ. A comparative study of systemic and unilateral intracranial delivery of scAAV9-hIFNβ in a bilateral GBM8 tumor model showed the systemic route to be the most effective approach for treating widely dispersed tumors. CONCLUSIONS: Systemic delivery of AAV9-IFNβ is an attractive approach for invasive and multifocal GBM treatment.
Authors: C J Streck; P V Dickson; C Y C Ng; J Zhou; M M Hall; J T Gray; A C Nathwani; A M Davidoff Journal: Cancer Gene Ther Date: 2006-01-01 Impact factor: 5.987
Authors: Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701
Authors: Keith L Ligon; John A Alberta; Alvin T Kho; Jennifer Weiss; Mary R Kwaan; Catherine L Nutt; David N Louis; Charles D Stiles; David H Rowitch Journal: J Neuropathol Exp Neurol Date: 2004-05 Impact factor: 3.685
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Maire F Osborn; Andrew H Coles; Diane Golebiowski; Dimas Echeverria; Michael P Moazami; Jonathan K Watts; Miguel Sena-Esteves; Anastasia Khvorova Journal: Mol Cancer Ther Date: 2018-04-13 Impact factor: 6.261
Authors: Kayla A Quirin; Jason J Kwon; Arafat Alioufi; Tricia Factora; Constance J Temm; Max Jacobsen; George E Sandusky; Kim Shontz; Louis G Chicoine; K Reed Clark; Joshua T Mendell; Murray Korc; Janaiah Kota Journal: Mol Ther Methods Clin Dev Date: 2017-09-30 Impact factor: 6.698